IRVINE, Calif. (AP) _ Endologix Inc. (ELGX) on Wednesday reported a loss of $24.9 million in its fourth quarter.
The Irvine, California-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs and restructuring costs, were 22 cents per share.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.
The medical device company posted revenue of $47.5 million in the period, also falling short of Street forecasts. Four analysts surveyed by Zacks expected $48.6 million.
For the year, the company reported that its loss widened to $154.7 million, or $1.91 per share. Revenue was reported as $192.9 million.
Endologix expects a full-year loss of 76 cents to 70 cents per share, with revenue in the range of $193 million to $200 million.
Endologix shares have risen 14 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $6.53, a drop of 13 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ELGX at https://www.zacks.com/ap/ELGX
Keywords: Endologix, Earnings Report